Clearmind Medicine shares surge 30.05% premarket after positive Phase I/IIa trial results for AUD drug CMND-100 show strong safety and treatment adherence.

Clearmind Medicine surged 30.05% in premarket trading following two key developments: the filing of an Israeli patent for its novel non-hallucinogenic neuroplastogen therapy for depression and the announcement of positive top-line results from the first cohort of its FDA-approved Phase I/IIa trial for CMND-100, a MEAI-based treatment for Alcohol Use Disorder (AUD). The patent filing, part of a collaboration with Neurothera Labs, strengthens Clearmind’s intellectual property portfolio, while the clinical trial results highlighted a favorable safety profile, no serious adverse events, and high treatment adherence, positioning CMND-100 as a potential breakthrough therapy. These milestones, particularly the positive trial data for a major unmet medical need, likely drove investor optimism, reflecting the company’s progress in advancing psychedelic-derived therapeutics for underserved conditions.